The revised buyback price represents a premium of nearly 16% to Wednesday’s closing price.
However, the number of shares proposed to be bought back has been reduced to 87.3 lakh shares from 95.6 lakh shares earlier. The revised buyback size represents up to 0.87% of the company’s total paid-up equity share capital.
The record date for the buyback is yet to be announced.
This marks the third share buyback approved by Zydus Lifesciences. The company had previously undertaken buybacks in 2022 and 2024.
In 2022, Zydus executed a ₹750 crore buyback through the tender offer route, repurchasing 1.15 crore shares at ₹650 apiece. In 2024, the company carried out another buyback worth ₹600 crore at ₹1,005 per share, involving 59.7 lakh shares. Promoters had participated in both buybacks.
Most of the company’s buybacks have been conducted through the tender offer route.
As of the March quarter, promoters held a 75% stake in the company. Domestic mutual funds owned 4.88%, led by PPFAS Mutual Fund and Kotak Mahindra Asset Management Company, while Life Insurance Corporation of India held a 5.56% stake.
Foreign portfolio investors owned 6.95%, while retail investors held 4.8%.
Shares of Zydus Lifesciences rose 0.65% on Wednesday to settle at ₹1,085.95. The stock has gained more than 19% over the last one month.
First Published: May 29, 2026 7:25 AM IST
